Firms

Kurma Partners

Kurma Partners

kurmapartners.com

Kurma Partners is a European healthcare and biotechnology investment firm founded in 2009, based in Paris with investing activity in Germany. It finances companies from scientific company creation and early development through expansion, across Biofund, Diagnostic and Growth Opportunities strategies. Working with European academic research groups, it helps translate discoveries into medicines, medical devices and diagnostics. Its neuroscience investments include Synendos Therapeutics, developing endocannabinoid-system drugs for CNS disorders.

Founded
—
Type
Venture capital

Funds7

  • Kurma Biofund I€51M

    Life-sciences seed and company-creation fund launchedNovember2009,EUR51M,invested11companies including5createdwithresearchinstitutes. Noinventedday.

  • Kurma Biofund II€55M

    Venture and company creation therapeutic biotechnology fund with focusonrarediseases. EUR55M and2013closingyearpermanager, noexactdayasserted.

  • Kurma Biofund III€160M

    Venture and company creation therapeutic biotechnology fund, primarilyEurope. Manager lists EUR160M, establishment/closingyear2018 onsummary; finalclose datedApr29,2020 inmanagernews, no2018fakefull day.

  • Kurma Biofund IV€215M

    Therapeutics venture and company creation fund. Final closing announced April24,2026 at EUR215M, superseding older fund page EUR158M and 2024 EUR140M first close; EUR250M was a target. About20investments planned,11completed by finalclose.

  • Kurma Diagnostics€35M

    Seed fund for disruptive diagnostics; manager lists EUR35M and closing2015, while narrative saysapproximately35M. Exactclosingdayunpublished.

  • Kurma Diagnostics II€83M

    Seed-stage digital diagnostics and healthcare digital transformation. Manager lists EUR83M and 2021 first-closing year; exactday notasserted.

  • Kurma Growth Opportunities€167M

    Growth, late-stage and crossover healthcare investing across therapeutics, diagnostics, HealthTech and selected MedTech/life-science tools. Manager lists EUR167M and closing2024, no exactday asserted.

Team

Operations and support

Alain HorvaisPartner, Diagnostic
Amanda GettPartner, Biofund
Anna TchorzewskaAssociate, Biofund
Benjamin BelotPartner, Diagnostic
Cyril BedranFinance Director
Daniel PareraPartner Germany, Growth Opportunities
Fatima BoubnadManagement Assistant
Florence de CoorebyterAssociate, Biofund
Hadrien BouchezPartner, Biofund
Jean-François RivassouPartner, Growth Opportunities
Laura AchachAssociate, Diagnostic
Louise-Marie RakotoarisonAnalyst, Diagnostic
Maylis DeschampsAssociate, Growth Opportunities
Muriel DomineGeneral Secretary and Head of Compliance and Legal
Ornella GomisFinancial Controller
Peter NeubeckPartner Germany, Biofund
Philippe PeltierPartner, Diagnostic
Rémi DrollerManaging Partner, Biofund
Samantha ZennouAssociate, Diagnostic
Sonny GuilhemSenior Financial Controller
Steffi MingaOffice Manager
Thierry LaugelManaging Partner, Biofund

Co-investing

Angelini Ventures
Argobio Studio
Bpifrance
CARMA FUND
High-Tech Gründerfonds

Investments